Spark Innovation • expand access •
In today’s BD&L landscape, science alone is no longer enough.
Alphabet Consulting bridges science, strategy, and culture to drive cross-border partnerships, with deep expertise in dealmaking and market entry—especially in China. China currently has:
K
Active biopharma companies
%
of global innovative pipeline
K
Active drugs in development
Clinical trial registrations
First-in-class drugs in 2024
Major biotech clusters
Emerging Biotech
The strategy behind the science
We help clients identify high-potential assets, execute in- and out-licensing deals, and navigate complex markets—especially in China and other emerging innovation hubs.
Optimization
Why us
Uniquely positioned
Personalized & flexible
We adapt to client needs in real time to ensure mutual success.
Deep market & government expertise
Our strong connections with local regulators, industry leaders, and investors offer unique access.
More effective BD&L
We focus on direct decision-maker engagement to accelerate deal closure and reduce inefficiencies.
China-specific strategy
Western firms often struggle in China due to a lack of localized expertise. We eliminate that gap.
Let's chat!
with us.